Yüklüyor......
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
INTRODUCTION: Nintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event profile that is manageable for most patients. We used data from six clinical trials to characterise the safety and t...
Kaydedildi:
| Yayımlandı: | BMJ Open Respir Res |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6530503/ https://ncbi.nlm.nih.gov/pubmed/31179001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2018-000397 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|